Local therapeutic strategies for neurocutaneous dysesthesia: from capsaicin to cannabinoids.
Abstract
[BACKGROUND] Neurocutaneous dysesthesia (ND) is characterized by abnormal skin sensations such as pruritus or burning without an underlying skin condition. It is caused by nerve damage or compression. Location and extent of symptoms vary greatly depending on the affected somatosensory site(s). Treatment is challenging and step-by-step guidelines are lacking. Local therapy offers a valuable first step, especially in mild cases or when systemic agents are contraindicated. Although numerous studies have described a variety of local treatment options for ND, no clear overview of these options existed.
[AIM] In this review, we provide an overview of available local treatment modalities for ND and explain their mechanisms of action.
[FINDINGS] The following local treatment options are described: capsaicin, calcineurin inhibitors, menthol, pramoxine/lidocaine/prilocaine, ambroxol, phenytoin, strontium, amitriptyline, doxepin, duloxetine, baclofen, gabapentin, cannabinoids, loperamide, naltrexone, clonidine, prazosin, acetylsalicylic acid, diclofenac, aprepitant, ketamine, calamine, polidocanol, and botulinum toxin type A.
[CONCLUSIONS] Local therapy offers a valuable and often well-tolerated first step in managing ND. Unfortunately, high-quality evidence is scarce and treatment efficacy remains unpredictable. Clinicians are advised to start with low concentrations, discuss off-label use, and monitor for side effects. Until robust guidelines are available, a cautious trial-and-error approach remains the cornerstone of management.
[AIM] In this review, we provide an overview of available local treatment modalities for ND and explain their mechanisms of action.
[FINDINGS] The following local treatment options are described: capsaicin, calcineurin inhibitors, menthol, pramoxine/lidocaine/prilocaine, ambroxol, phenytoin, strontium, amitriptyline, doxepin, duloxetine, baclofen, gabapentin, cannabinoids, loperamide, naltrexone, clonidine, prazosin, acetylsalicylic acid, diclofenac, aprepitant, ketamine, calamine, polidocanol, and botulinum toxin type A.
[CONCLUSIONS] Local therapy offers a valuable and often well-tolerated first step in managing ND. Unfortunately, high-quality evidence is scarce and treatment efficacy remains unpredictable. Clinicians are advised to start with low concentrations, discuss off-label use, and monitor for side effects. Until robust guidelines are available, a cautious trial-and-error approach remains the cornerstone of management.
추출된 의학 개체 (NER)
| 유형 | 영어 표현 | 한국어 / 풀이 | UMLS CUI | 출처 | 등장 |
|---|---|---|---|---|---|
| 시술 | botulinum toxin
|
보툴리눔독소 주사 | dict | 1 | |
| 해부 | skin
|
scispacy | 1 | ||
| 해부 | nerve
|
scispacy | 1 | ||
| 약물 | ketamine
|
C0022614
ketamine
|
scispacy | 1 | |
| 약물 | calamine
|
C0357929
calamine
|
scispacy | 1 | |
| 약물 | cannabinoids
|
scispacy | 1 | ||
| 약물 | [BACKGROUND] Neurocutaneous dysesthesia
|
scispacy | 1 | ||
| 약물 | pramoxine/lidocaine/prilocaine
|
scispacy | 1 | ||
| 약물 | ambroxol
|
scispacy | 1 | ||
| 약물 | polidocanol
|
scispacy | 1 | ||
| 약물 | [CONCLUSIONS]
|
scispacy | 1 | ||
| 약물 | lidocaine
|
리도카인 | dict | 1 | |
| 약물 | capsaicin
|
C0006931
capsaicin
|
scispacy | 1 | |
| 약물 | menthol
|
C0025368
menthol
|
scispacy | 1 | |
| 약물 | phenytoin
|
C0031507
phenytoin
|
scispacy | 1 | |
| 약물 | strontium
|
C0038467
strontium
|
scispacy | 1 | |
| 약물 | amitriptyline
|
C0002600
amitriptyline
|
scispacy | 1 | |
| 약물 | doxepin
|
C0013085
doxepin
|
scispacy | 1 | |
| 약물 | duloxetine
|
C0245561
duloxetine
|
scispacy | 1 | |
| 약물 | baclofen
|
C0004609
baclofen
|
scispacy | 1 | |
| 약물 | gabapentin
|
C0060926
gabapentin
|
scispacy | 1 | |
| 약물 | loperamide
|
C0023992
loperamide
|
scispacy | 1 | |
| 약물 | naltrexone
|
C0027360
naltrexone
|
scispacy | 1 | |
| 약물 | clonidine
|
C0009014
clonidine
|
scispacy | 1 | |
| 약물 | prazosin
|
C0032912
prazosin
|
scispacy | 1 | |
| 약물 | acetylsalicylic acid
|
C0004057
aspirin
|
scispacy | 1 | |
| 약물 | diclofenac
|
C0012091
diclofenac
|
scispacy | 1 | |
| 약물 | aprepitant
|
C1176306
aprepitant
|
scispacy | 1 | |
| 질환 | somatosensory
|
scispacy | 1 | ||
| 질환 | neurocutaneous dysesthesia
|
scispacy | 1 | ||
| 질환 | abnormal skin sensations
|
scispacy | 1 | ||
| 질환 | pruritus
|
C0033774
Pruritus
|
scispacy | 1 | |
| 질환 | nerve damage
|
C0161479
Nerve injury
|
scispacy | 1 | |
| 기타 | calcineurin
|
scispacy | 1 |
MeSH Terms
Humans; Cannabinoids; Capsaicin; Paresthesia; Neurocutaneous Syndromes; Treatment Outcome; Administration, Cutaneous
🔗 함께 등장하는 도메인
이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들
관련 논문
- Comparative efficacy of intralesional therapies for keloid scars: a network meta-analysis.
- Comparative effects of pharmacological interventions in the prophylactic treatment of tension-type headache: systematic review and network meta-analysis.
- Adverse neurological events following botulinum toxin type A: A case series of post-injection seizures and paralysis.
- Decreased utilization of component separation techniques over time in complex abdominal wall reconstruction following introduction of preoperative botulinum toxin A.
- Current Perspectives on Pectoralis Minor Syndrome: A Narrative Review.